share_log

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8

Canaccord Genuity维持对Cardiol Therapeutics的买入,将目标股价提高至8美元
Benzinga ·  2024/05/23 19:57

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $6 to $8.

Canaccord Genuity分析师爱德华·纳什维持Cardiol Therapeutics(纳斯达克股票代码:CRDL)的买入并将目标股价从6美元上调至8美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发